文献速递冠心病心力衰竭与心肌病

沙库巴曲缬沙坦与雷米普利对急性心梗后心脏结构与功能的影响:PARADISE-MI超声心动图亚研究

Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy.
PubMed 文献 · Circulation · 2022-09-09

PARADISE-MI超声心动图预设亚研究纳入544例高危急性心梗患者,随机接受沙库巴曲缬沙坦200 mg或雷米普利5 mg每日两次,8个月随访457例(84%)。两组LVEF与左房容积变化无显著差异,但沙库巴曲缬沙坦组左室舒张末容积增加更少、左室质量指数下降更多、舒张功能指标改善更明显。

要点

  • 急性心梗后8个月,沙库巴曲缬沙坦与雷米普利在LVEF和左房容积变化上无显著差异。
  • 沙库巴曲缬沙坦组左室扩大更少、充盈压改善更明显,提示可能减缓不良重构。
  • 基线左室大小、收缩功能及舒张指标可预测心血管死亡或新发心衰。

核心结论

  • 急性心梗后使用沙库巴曲缬沙坦较雷米普利未改变8个月LVEF或左房容积,但左室扩大更少、充盈压改善更明显。
  • 左室大小、收缩功能和舒张特性可预测该现代治疗队列中心梗后心血管死亡和新发心衰。

研究设计与样本

  • PARADISE-MI预设超声心动图亚研究,544例高危急性心梗患者随机接受沙库巴曲缬沙坦200 mg或雷米普利5 mg每日两次。
  • 随机化后及8个月时行方案超声心动图,由盲法核心实验室判读,采用ANCOVA校正基线值和入组地区。
  • 457例(84%)完成8个月随访超声,其中沙库巴曲缬沙坦组228例、雷米普利组229例。

主要发现

  • 两组LVEF变化无显著差异(P=0.79),左房容积变化亦无显著差异(P=0.62)。
  • 沙库巴曲缬沙坦组左室舒张末容积增加更少(P=0.025),左室质量指数下降更多(P=0.037)。
  • 沙库巴曲缬沙坦组组织多普勒e'lat升高(P=0.005)、E/e'lat降低(P=0.045)、三尖瓣反流峰值速度降低(P=0.024)。
  • 上述差异校正基线特征后仍显著。
  • 基线LVEF、左室舒张末容积、左室收缩末容积、左室质量指数、左房容积及多普勒舒张指标与心血管死亡或新发心衰风险相关。

关键数值与推荐

  • 研究对象平均年龄64±12岁,女性占26%,平均LVEF 42±12%,平均左房容积49±17 mL。
  • 沙库巴曲缬沙坦目标剂量200 mg每日两次,雷米普利目标剂量5 mg每日两次。

临床怎么用

  • 急性心梗后高危患者选用沙库巴曲缬沙坦或雷米普利时,LVEF与左房容积改善预期相似。
  • 若关注左室重构与充盈压,沙库巴曲缬沙坦在超声指标上可能更有优势,但需结合临床结局综合判断。
  • 基线及随访超声的左室大小、收缩与舒张指标有助于心梗后心衰和死亡风险分层。

局限性

  • 本研究为PARADISE-MI预设超声亚研究,仅544例纳入且84%完成随访超声。
  • 超声终点为8个月时的结构与功能替代指标,非临床硬终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Angiotensin-converting enzyme inhibitors attenuate left ventricular (LV) enlargement after acute myocardial infarction (AMI). Preclinical data suggest similar benefits with combined angiotensin receptor neprilysin inhibition, but human data are conflicting. The PARADISE-MI Echo Study (Prospective ARNI Versus ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction) tested the effect of sacubitril/valsartan compared with ramipril on LV function and adverse remodeling after high risk-AMI. METHODS: In a prespecified substudy, 544 PARADISE-MI participants were enrolled in the Echo Study to undergo protocol echocardiography at randomization and after 8 months. Patients were randomized within 0.5 to 7 days of presentation with their index AMI to receive a target dose of sacubitril/valsartan 200 mg or ramipril 5 mg twice daily. Echocardiographic measures were performed at a core laboratory by investigators blinded to treatment assignment. The effect of treatment on change in echo measures was assessed with ANCOVA with adjustment for baseline value and enrollment region. The primary end points were change in LV ejection fraction (LVEF) and left atrial volume (LAV), and prespecified secondary end points included changes in LV end-diastolic and end-systolic volumes. RESULTS: Mean age was 64±12 years; 26% were women; mean LVEF was 42±12%; and LAV was 49±17 mL. Of 544 enrolled patients, 457 (84%) had a follow-up echo at 8 months (228 taking sacubitril/valsartan, 229 taking ramipril). There was no significant difference in change in LVEF (P=0.79) or LAV (P =0.62) by treatment group. Patients randomized to sacubitril/valsartan demonstrated less increase in LV end-diastolic volume (P=0.025) and greater decline in LV mass index (P=0.037), increase in tissue Doppler e'lat (P=0.005), decrease in E/e'lat (P=0.045), and decrease in tricuspid regurgitation peak velocity (P=0.024) than patients randomized to ramipril. These differences remained significant after adjustment for differences in baseline characteristics. Baseline LVEF, LV end-diastolic volume, LV end-systolic volume, LV mass index, LAV, and Doppler-based diastolic indices were associated with risk of cardiovascular death or incident heart failure. CONCLUSIONS: Treatment with sacubitril/valsartan compared with ramipril after AMI did not result in changes in LVEF or LAV at 8 months. Patients randomized to sacubitril/valsartan had less LV enlargement and greater improvement in filling pressure. Measures of LV size, systolic function, and diastolic properties were predictive of cardiovascular death and incident heart failure after AMI in this contemporary, well-treated cohort. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02924727.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Shah, Claggett, Prasad, et al. Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy. Circulation. 2022. PMID: 36082663. doi:10.1161/CIRCULATIONAHA.122.059210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。